Increasing Access to HCT for Sickle Cell Disease
Connecting Transplant Centers and Sickle Cell Programs
Release date: Sept. 28, 2022
Hematopoietic cell transplantation (HCT) is a potential curative option for patients with sickle cell disease (SCD). However, many patients and health care providers remain unaware of the treatment option.
During this on-demand roundtable, our expert HCT and SCD panelists will discuss some of the latest research and outcomes in HCT for SCD, as well as share models for outreach and engagement between transplant centers and SCD programs.
Attendees will improve their understanding of:
- The role of HCT in the treatment of SCD
- Recent trends in access to and outcomes of HCT for SCD
- Models for outreach and engagement to improve shared, coordinated care between transplant centers treating SCD patients and community hematology/oncology or SCD programs
- How transplant centers and hematology/oncology or SCD providers can work together to improve health equity and access to HCT
- Patient resources, such as the Sickle Cell Warrior Program and HLA Today
Earn CME Credit
If you are interested in claiming CME credit, be sure to complete the evaluation included in the webinar activity in the American Society for Transplantation and Cellular Therapy (ASTCT) Learning Center. If you have any trouble with this process, please reach out to email@example.com or firstname.lastname@example.org for assistance.
Elizabeth Stenger, MD, MSc
Blood and Marrow Transplant Physician
Aflac Cancer & Blood Disorders Center
Children's Healthcare of Atlanta/Emory University
Ashish Gupta, MD, MPH
Pediatric Blood and Marrow Transplant
University of Minnesota
Samuel Anim, MD, MSc
Sanford Roger Maris Cancer Center
Heather Stefanski, MD, PhD (moderator)
Vice President of Medical Services
National Marrow Donor Program/Be The Match
Community hematology/oncology physicians and nurses; HCT physicians, nurses and coordinators; NMDP/Be The Match clinical operations partners; and advanced level case managers and health professionals.
This activity is jointly provided by The France Foundation, National Marrow Donor Program, and American Society for Transplantation and Cellular Therapy (ASTCT).
In support of improving patient care, this activity has been planned and implemented by The France Foundation, National Marrow Donor Program, and American Society for Transplantation and Cellular Therapy. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit DesignationPhysician Credit Designation
The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other healthcare professionals completing this course will be issued a statement of participation.